Novartis loses global development head to Gates Foundation
pharmafile | September 14, 2011 | News story | Research and Development | Bill and Melinda Gates Foundation, Novartis, appointment
Novartis’ global head of development Trevor Mundel is to leave the company and take a senior position at The Bill and Melinda Gates Foundation.
He will remain with Novartis until 1 December, after which he will take up the role of executive director of the Foundation’s Global Health Program.
At Novartis Mundel’s responsibilities included overseeing the development of drug candidates provided by the Novartis Institutes for BioMedical Research (NIBR) or the company’s licensing partners.
Prior to joining Novartis, he worked for Warner Lambert and Pfizer in senior clinical development roles, including director in central nervous system clinical development and as head of experimental Medicine, respectively.
Novartis said it would name Mundel’s successor shortly.
Dominic Tyer
Related Content

Scotland starts newborn screening for SMA
As part of a two-year evaluation funded by the Scottish government and Novartis, Scotland will …

Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

Novartis candidate for Sjögren’s disease presents positive results
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …





